<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00598676</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. S02607</org_study_id>
    <nct_id>NCT00598676</nct_id>
  </id_info>
  <brief_title>3 Limus Agent Eluting Stents With Different Polymer Coating</brief_title>
  <acronym>ISAR-TEST-4</acronym>
  <official_title>Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting STents (ISAR-TEST 4): Prospective, Randomized Trial of 3-limus Agent-eluting Stents With Different Polymer Coatings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether biodegradable polymer based rapamycin-eluting
      stent performs equal to permanent polymer based everolimus- and rapamycin-eluting stents
      regarding reduction of adverse cardiac events at one year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Drug-eluting stents significantly reduce in-stent restenosis and the subsequent need for
      target vessel revascularisation compared with bare metal stents. Although this applies to the
      vast majority of patients, intimal hyperplasia and in-stent restenosis have not been
      completely eliminated and remain to occur in certain high risk subgroups. Thus there is
      ongoing research for new, potentially more effective and safe drug-eluting stent systems.

      One direction of extensive research is the search of new polymers such as biodegradable
      polymers which allow a controlled drug-release and disappear with time, reducing the
      probability of polymer-induced chronic inflammation on the vessel wall.

      Another direction is finding new drugs to suppress neointimal hyperplasia. Promising
      preclinical and clinical results suggest that the Everolimus eluting stent platform might
      provide potential improvements over prior generations of drug-eluting stents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end point of the study is a combined endpoint of cardiac death, myocardial infarction related to the target vessel or revascularization related to the target lesion.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-segment binary restenosis at follow-up angiography</measure>
    <time_frame>6-8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Lumen Loss at follow-up angiography</measure>
    <time_frame>6-8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of stent thrombosis (by ARC definition)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2600</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>BPRES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>biodegradable polymer rapamycin-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPRES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>permanent polymer rapamycin-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPEES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>permanent polymer everolimus-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>biodegradable polymer Rapamycin-eluting stent</intervention_name>
    <description>due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted</description>
    <arm_group_label>BPRES</arm_group_label>
    <other_name>ISAR stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>permanent polymer rapamycin-eluting stent (Cypher)</intervention_name>
    <description>due to randomization, rapamycin-eluting stent with permanent polymer will be implanted</description>
    <arm_group_label>PPRES</arm_group_label>
    <other_name>Cypher</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>permanent polymer everolimus-eluting stent (Xience, Promus)</intervention_name>
    <description>due to randomization, everolimus-eluting stent with permanent polymer will be implanted</description>
    <arm_group_label>PPEES</arm_group_label>
    <other_name>Xience</other_name>
    <other_name>Promus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia
             in the presence of ≥ 50% de novo stenosis located in native coronary vessels.

          -  Written, informed consent by the patient or her/his legally-authorized representative
             for participation in the study.

          -  In women with childbearing potential a negative pregnancy test is mandatory

        Exclusion Criteria:

          -  Target lesion located in the left main trunk.

          -  Target lesion located in the bypass graft.

          -  In-stent restenosis.

          -  Cardiogenic shock.

          -  Malignancies or other comorbid conditions (for example severe liver, renal and
             pancreatic disease) with life expectancy less than 12 months or that may result in
             protocol non-compliance.

          -  Known allergy to the study medications: Clopidogrel, Rapamycin, Everolimus, stainless
             steel or cobalt chrome.

          -  Inability to take clopidogrel for at least 6 months.

          -  Pregnancy (present, suspected or planned) or positive pregnancy test.

          -  Previous enrollment in this trial.

          -  Patient's inability to fully cooperate with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Schoemig, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL, Schulz S, Pache J, Fusaro M, Seyfarth M, Schömig A, Mehilli J; Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Investigators. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J. 2009 Oct;30(20):2441-9. doi: 10.1093/eurheartj/ehp352. Epub 2009 Aug 30.</citation>
    <PMID>19720642</PMID>
  </results_reference>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2008</study_first_posted>
  <last_update_submitted>March 12, 2010</last_update_submitted>
  <last_update_submitted_qc>March 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. A. Schömig</name_title>
    <organization>Deutsches Herzzentrum Munich</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

